Screener
Taysha Gene Therapies, Inc. TSHA Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344610
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies - Note 13 | ||
| Stockholders' equity | ||
| Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.00001 par value per share; 700,000,000 shares authorized and 325,302,280 and 285,051,648 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 3 | 3 |
| Additional paid-in capital | 1,186,843 | 958,427 |
| Accumulated other comprehensive income (loss) | 769 | (192) |
| Accumulated deficit | (800,349) | (711,300) |
| Total stockholders’ equity | 387,266 | 246,938 |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s common stock?
- Taysha Gene Therapies, Inc. (TSHA) reported common stock of $3K in Q2 2026.
- How has Taysha Gene Therapies, Inc.'s common stock changed year-over-year?
- Taysha Gene Therapies, Inc.'s common stock decreased by 0.0% year-over-year, from $3K to $3K.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s common stock?
- Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s common stock has grown at a 44.2% compound annual growth rate (CAGR), from $1K to $3K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Taysha Gene Therapies, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude